Plain-English translation of NCT05666700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 clinical trial testing cilta-cel, a type of immune cell therapy designed to fight a hard-to-treat form of blood cancer called extramedullary myeloma. The trial uses advanced imaging scans to track where the therapy cells travel in your body and how well they work against the cancer.
Extramedullary myeloma is a rare, aggressive form of blood cancer that often stops responding to standard treatments. This trial aims to better understand how the new treatment moves through the body and fights the cancer, which could help doctors improve results for patients like you in the future.
You will undergo a procedure to collect your white blood cells, which are then modified in a laboratory to create the therapy. The modified cells are infused back into your body through an IV, with some cells labeled so doctors can track them using special imaging scans (PET-MRI). You will have regular visits for blood work, imaging scans, and health check-ups to monitor how you respond to the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborators
Janssen, LP
Enrollment target
~10 participants
Started
December 2023
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.